A Parkinson substance from Danish medico giant Lundbeck shows good results.

As the only companies in the world Danish medico-company Lundbeck and its Israelic cooperator, Teva Pharmaceuticals, have a drug candidate, which cannot only treat symptoms in Parkinson patients but also postpone development of the disease. These are the findings from new top-line data from a phase 3 study of Azilect, according to the Danish daily news Børsen.

Lundbeck expects that the results significantly will influence sales, and in Teva they are even more encouraged and foresee a “dramatic increase in the market potential”, as the management  describes it. But contrary to Lundbeck, Teva holds the rights in the USA.

“The Parkinson market is full of old drugs and generic medicine and all together this is a very compact market. So it is very exciting that we now have data, which makes Azilect a stand alone product,” says head of communications and investor relations in Lundbeck, Jacob Tolstrup, and he continues:

“There is no doubt that this will have a significant impact on the sales. But this is topline data and now we have to find out how to use the data in our European marketing. This makes it difficult to present exact estimations of future sales,” says Jacob Tolstrup.

Exactly how much it is worth for Lundbeck is difficult to estimate, but a sales potential around EUR 150 mio. is a qualified guess, when it is calculated before withdrawel of the amount that Lundbeck pays Teva for the marketing rights in Europe and on international markets.